Transcriptomic recurrence score improves recurrence prediction for surgically treated patients with intermediate-risk clear cell kidney cancer.

Neal Patel,Alexander Hakansson,Shinji Ohtake,Peter Muraki, James A Proudfout,Yang Liu, Lisa Webber, Arkaitz Ibarra,Vinnie Y T Liu,Elai Davicioni,Karim Chamie,Allan Pantuck,Brian Shuch

Cancer medicine（2023）

引用 0|浏览15

暂无评分

摘要

Transcriptomic recurrence scores improve risk prediction even when controlling for clinicopathologic factors. Utility may be best suited for intermediate-risk patients who have heterogeneous outcomes and further refinement for clinical utility is warranted.

查看译文

关键词

adjuvant therapy,kidney cancer,transcriptomics

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要